{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:47Z","timestamp":1792068887502,"version":"4.4.0"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010095","name":"Hauts-de-France Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bmcl.2026.130781","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:54:26Z","timestamp":1789602866000},"page":"130781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quinolin(on)es and pyridin(on)es as promising scaffolds against mycobacterial infections"],"prefix":"10.1016","volume":"142","author":[{"given":"Marie","family":"Gr\u00e9verie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dassonville-Klimpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Andr\u00e9jak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Sonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130781_bb0005","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.meegid.2019.01.017","article-title":"Nontuberculous mycobacteria: insights on taxonomy and evolution","volume":"72","author":"Turenne","year":"2019","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0010","article-title":"Epidemiology and laboratory detection of non-tuberculous mycobacteria","volume":"10","author":"Xu","year":"2024","journal-title":"Heliyon"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130781_bb0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.arbr.2017.08.004","article-title":"Non-tuberculous mycobacteria. An emerging threat?","volume":"53","author":"Gonz\u00e1lez","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0020","unstructured":"World Health Organization Global Tuberculosis Report 2025; World Health Organization: Geneva, Switzerland, 2025; ISBN 978\u201392\u20134-011692-4, p.2, https:\/\/www.who.int\/publications\/b\/81626."},{"key":"10.1016\/j.bmcl.2026.130781_bb0025","unstructured":"World Health Organization Global Tuberculosis Report 2019; 23rd ed.; World Health Organization: Geneva, 2019; ISBN 978\u201392\u20134-156571-4, p.103, https:\/\/iris.who.int\/handle\/10665\/329368."},{"key":"10.1016\/j.bmcl.2026.130781_bb0030","article-title":"Non-tuberculous mycobacteria: clinical and laboratory characterisation (2009 and 2019)","volume":"151","author":"Lopes","year":"2022","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.bmcl.2026.130781_bb0035","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/CMR.15.4.716-746.2002","article-title":"Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria","volume":"15","author":"Brown-Elliott","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bmcl.2026.130781_bb0040","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3201\/2109.141634","article-title":"Mycobacterium abscessus complex infections in humans","volume":"21","author":"Lee","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9112366","article-title":"Application of bacteriophages for mycobacterial infections, from diagnosis to treatment","volume":"9","author":"Shield","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.bmcl.2026.130781_bb0050","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1007\/s00253-021-11349-0","article-title":"Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives","volume":"105","author":"Shleeva","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2024.116469","article-title":"96well-formatted CrfA assay for differentiation of Mycobacterium tuberculosis and non-tuberculous mycobacteria","volume":"110","author":"Wazahat","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0060","article-title":"Sex, ancestry, senescence, and aging (SAnSA) are stark drivers of nontuberculous mycobacterial pulmonary disease","volume":"26","author":"Fifor","year":"2022","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/RTI.0000000000000346","article-title":"Radiology of chronic cavitary infections","volume":"33","author":"Ketai","year":"2018","journal-title":"J Thorac Imaging"},{"key":"10.1016\/j.bmcl.2026.130781_bb0070","unstructured":"World Health Organization WHO Consolidated Operational Handbook on Tuberculosis. Module 4: Treatment and Care; 1st ed.; World Health Organization: Geneva, 2025; ISBN 978\u201392\u20134-010814-1, https:\/\/www.who.int\/publications\/i\/item\/9789240108141."},{"key":"10.1016\/j.bmcl.2026.130781_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101213","article-title":"Fluoroquinolone derivatives in the treatment of Mycobacterium tuberculosis infection","volume":"15","author":"Pais","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmcl.2026.130781_bb0080","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cpt.2261","article-title":"The treatment of tuberculosis","volume":"110","author":"Peloquin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2026.130781_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1394220","article-title":"Treatment for non-tuberculous mycobacteria: challenges and prospects","volume":"15","author":"Conyers","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy022","article-title":"Mycobacterium abscessus complex infections: a retrospective cohort study","volume":"5","author":"Sfeir","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: first FDA-approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int J Appl Basic Med Res"},{"key":"10.1016\/j.bmcl.2026.130781_bb0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4046\/trd.2016.79.2.74","article-title":"Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives","volume":"79","author":"Ryu","year":"2016","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128824","article-title":"Discovery and preclinical profile of Sudapyridine (WX-081), a novel anti-tuberculosis agent","volume":"71","author":"Huang","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130781_bb0110","doi-asserted-by":"crossref","unstructured":"Katritzky, A.R.; Ramsden, C.A.; Joule, J.A.; Zhdankin, V.V. Handbook of Heterocyclic Chemistry; 3rd ed.; Elsevier: Oxford, UK, 2010; ISBN 978\u20130\u201308-095843-9, doi:https:\/\/doi.org\/10.1016\/C2009-0-05547-0.","DOI":"10.1016\/C2009-0-05547-0"},{"key":"10.1016\/j.bmcl.2026.130781_bb0115","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021105","article-title":"The mycobacterial cell envelope--lipids","volume":"4","author":"Jackson","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bmcl.2026.130781_bb0120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/acs.jproteome.0c00650","article-title":"Cell envelope proteomics of mycobacteria","volume":"20","author":"Hermann","year":"2021","journal-title":"J Proteome Res"},{"key":"10.1016\/j.bmcl.2026.130781_bb0125","doi-asserted-by":"crossref","unstructured":"Vilch\u00e8ze, C.; Jacobs, W.R. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr 2019, 2(4), 1\u201337, doi:https:\/\/doi.org\/10.1128\/microbiolspec.MG M2-0014-2013.","DOI":"10.1128\/microbiolspec.MGM2-0014-2013"},{"key":"10.1016\/j.bmcl.2026.130781_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1056608","article-title":"Anti-tuberculosis drug development via targeting the cell envelope of Mycobacterium tuberculosis","volume":"13","author":"Xu","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0135","doi-asserted-by":"crossref","unstructured":"Roshdi Maleki, M. Genetic analysis of molecular mechanisms of drug resistance in Mycobacterium tuberculosis against four major first-line anti-tuberculosis drugs (Isoniazid, Rifampin, Ethambutol, and Pyrazinamide). IDR 2025, Volume 18, 4901\u20134915, doi:https:\/\/doi.org\/10.2147\/IDR.S542287.","DOI":"10.2147\/IDR.S542287"},{"key":"10.1016\/j.bmcl.2026.130781_bb0140","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1038\/s41467-023-39300-z","article-title":"DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds Pretomanid and Delamanid","volume":"14","author":"Abrahams","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2026.130781_bb0145","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.2147\/DDDT.S281639","article-title":"Profiling Pretomanid as a therapeutic option for TB infection: evidence to date","volume":"15","author":"Stancil","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmcl.2026.130781_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.717045","article-title":"Mechanism of action, resistance, synergism, and clinical implications of Delamanid against multidrug-resistant Mycobacterium tuberculosis","volume":"12","author":"Khoshnood","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0155","article-title":"Identification and characterization of endo-\u03b1-, exo-\u03b1-, and exo-\u03b2-d-arabinofuranosidases degrading lipoarabinomannan and arabinogalactan of mycobacteria","volume":"14","author":"Shimokawa","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2026.130781_bb0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0008-6215(87)80065-4","article-title":"Demonstration that the galactosyl and the arabinosyl residues in the cell wall arabinogalactan of Mycobacterium leprae and Mycobacterium tuberculosis are furanoid","volume":"166","author":"Wallners","year":"1987","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.bmcl.2026.130781_bb0165","doi-asserted-by":"crossref","first-page":"18200","DOI":"10.1016\/S0021-9258(17)44738-7","article-title":"Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cell walls","volume":"265","author":"McNeil","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01279-17","article-title":"Mutations within embCAB are associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China","volume":"62","author":"Sun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0175","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00216-016-9857-5","article-title":"Towards an automated analysis of bacterial peptidoglycan structure","volume":"409","author":"Bern","year":"2017","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102151","article-title":"Expression of a novel mycobacterial phosphodiesterase successfully lowers cAMP levels resulting in reduced tolerance to cell wall\u2013targeting antimicrobials","volume":"298","author":"Thomson","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0185","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/bcp.13975","article-title":"Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis","author":"Mulubwa","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0190","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/fmb-2016-0208","article-title":"LdtMav2, a nonclassical transpeptidase and susceptibility of Mycobacterium avium to carbapenems","volume":"12","author":"Mattoo","year":"2017","journal-title":"Future Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0195","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00149-25","article-title":"Sudapyridine (WX-081) inhibits Mycobacterium tuberculosis by targeting ATP synthase and upregulating host innate immunity","volume":"10","author":"Li","year":"2025","journal-title":"mSphere"},{"key":"10.1016\/j.bmcl.2026.130781_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-01173-z","article-title":"Bedaquiline inhibits the yeast and human mitochondrial ATP synthases","volume":"3","author":"Luo","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0205","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","article-title":"Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase","volume":"286","author":"Yano","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051489","article-title":"Why two? On the role of (a-)symmetry in negative supercoiling of DNA by gyrase","volume":"19","author":"Klostermeier","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130781_bb0215","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/cr030112j","article-title":"Rifamycinmode of action, resistance, and biosynthesis","volume":"105","author":"Floss","year":"2005","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2026.130781_bb0220","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","article-title":"The role of amikacin in the treatment of nontuberculous mycobacterial disease","volume":"22","author":"Raaijmakers","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2019.151380","article-title":"Tigecycline resistance may be associated with dysregulated response to stress in Mycobacterium abscessus","volume":"310","author":"Ng","year":"2020","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijantimicag.2012.09.005","article-title":"The emergence of clinical resistance to tigecycline","volume":"41","author":"Sun","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmcl.2026.130781_bb0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41594-022-00723-9","article-title":"Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics","volume":"29","author":"Tsai","year":"2022","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0240","doi-asserted-by":"crossref","first-page":"814","DOI":"10.22207\/JPAM.16.2.41","article-title":"A comprehensive review and update on epidemiology, symptomatology and management of nontuberculous mycobacteria (NTM)","volume":"16","author":"Kalpana","year":"2022","journal-title":"J Pure Appl Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0245","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bmcl.2026.130781_bb0250","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8168750","article-title":"Nontuberculous mycobacterial resistance to antibiotics and disinfectants: challenges still ahead","volume":"2022","author":"Tarashi","year":"2022","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.bmcl.2026.130781_bb0255","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.201208-1500ED","article-title":"Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others","volume":"186","author":"Stout","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmcl.2026.130781_bb0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"CHEST"},{"key":"10.1016\/j.bmcl.2026.130781_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.00681","article-title":"New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria","volume":"8","author":"Nasiri","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0270","article-title":"Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance","volume":"33","author":"Lale Ngema","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0275","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1128\/AAC.47.12.3799-3805.2003","article-title":"ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates","volume":"47","author":"Morlock","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0280","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1038\/emi.2013.38","article-title":"Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis","volume":"2","author":"Zhang","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.bmcl.2026.130781_bb0285","first-page":"1","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang","year":"2013","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.bmcl.2026.130781_bb0290","doi-asserted-by":"crossref","DOI":"10.1007\/s00284-022-03032-y","article-title":"Mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis: a review and update","volume":"79","author":"Rajendran","year":"2022","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0295","doi-asserted-by":"crossref","unstructured":"Li, M.; Lu, J.; Lu, Y.; Xiao, T.; Liu, H.; Lin, S.; Xu, D.; Li, G.; Zhao, X.; Liu, Z.; et al. rpoB mutations and effects on rifampin resistance in Mycobacterium tuberculosis. IDR 2021, Volume 14, 4119\u20134128, doi:https:\/\/doi.org\/10.2147\/IDR.S333433, Infect Drug Resist.","DOI":"10.2147\/IDR.S333433"},{"key":"10.1016\/j.bmcl.2026.130781_bb0300","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1016\/S2666-5247(21)00175-0","article-title":"Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis","volume":"2","author":"Ismail","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.bmcl.2026.130781_bb0305","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.06154-11","article-title":"New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure","volume":"56","author":"Segala","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0310","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jac\/dks033","article-title":"gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis","volume":"67","author":"Sirgel","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0315","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1128\/AAC.03002-15","article-title":"Geographic differences in the contribution of ubiA mutations to high-level ethambutol resistance in Mycobacterium tuberculosis","volume":"60","author":"Lingaraju","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0320","doi-asserted-by":"crossref","unstructured":"Nguyen, V.L.; Elck, K.L.; Gan, M.; Miner, T.A.; Friedland, A.E.; Carey, A.F. Macrolide resistance in Mycobacterium abscessus: current insights and future perspectives. JAC Antimicrob Resist 2025, 7(2), 1\u201310, doi:doi.org\/https:\/\/doi.org\/10.1093\/jacamr\/dlaf047.","DOI":"10.1093\/jacamr\/dlaf047"},{"key":"10.1016\/j.bmcl.2026.130781_bb0325","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0330","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmcl.2026.130781_bb0335","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/JB.180.22.5836-5843.1998","article-title":"Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis","volume":"180","author":"A\u00ednsa","year":"1998","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0340","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1128\/AAC.48.7.2415-2423.2004","article-title":"Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis","volume":"48","author":"Li","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0345","doi-asserted-by":"crossref","unstructured":"Machado, D.; Cannalire, R.; Santos Costa, S.; Manfroni, G.; Et., A. Boosting effect of 2-phenylquinoline efflux inhibitors in combination with macrolides against Mycobacterium smegmatis and Mycobacterium avium. ACS Infect Dis 2015, 1(12), 593\u2013603, doi:https:\/\/doi.org\/10.1021\/acsinfecdis.5b00052.","DOI":"10.1021\/acsinfecdis.5b00052"},{"key":"10.1016\/j.bmcl.2026.130781_bb0350","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01000-19","article-title":"The TetR family transcription factor MAB_2299c regulates the expression of two distinct MmpS-MmpL efflux pumps involved in cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus","volume":"63","author":"Guti\u00e9rrez","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0355","doi-asserted-by":"crossref","first-page":"12824","DOI":"10.1074\/jbc.M110751200","article-title":"The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase","volume":"277","author":"Vannelli","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0360","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1084\/jem.20062100","article-title":"Mechanism of thioamide drug action against tuberculosis and leprosy","volume":"204","author":"Wang","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmcl.2026.130781_bb0365","doi-asserted-by":"crossref","unstructured":"Laborde, J.; Deraeve, C.; Duhayon, C.; Pratviel, G.; Et., A. Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites. Organic & Biomolecular Chemistry 2016, 14(37), 8848\u20138858, doi:https:\/\/doi.org\/10.1039\/C6OB01561A, Org Biomol Chem.","DOI":"10.1039\/C6OB01561A"},{"key":"10.1016\/j.bmcl.2026.130781_bb0370","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.3390\/molecules15042791","article-title":"Elucidating drug-enzyme interactions and their structural basis for improving the affinity and potency of isoniazid and its derivatives based on computer modeling approaches","volume":"15","author":"Punkvang","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130781_bb0375","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02508-19","article-title":"KatG as counterselection marker for nontuberculous mycobacteria","volume":"64","author":"Gagliardi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0380","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00463-19","article-title":"Daily dosing for bedaquiline in patients with tuberculosis","volume":"63","author":"Salinger","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0385","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01393-08","article-title":"Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue","volume":"53","author":"Haagsma","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0390","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tube.2019.06.005","article-title":"A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity","volume":"117","author":"Patel","year":"2019","journal-title":"Tuberculosis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0395","doi-asserted-by":"crossref","unstructured":"Andries, K.; Verhasselt, P.; Guillemont, J.; G\u00f6hlmann, H.W.H.; Et., A. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307(5707), 223\u2013227, doi:https:\/\/doi.org\/10.1126\/science.1106753.","DOI":"10.1126\/science.1106753"},{"key":"10.1016\/j.bmcl.2026.130781_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500106","article-title":"Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline","volume":"1","author":"Preiss","year":"2015","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmcl.2026.130781_bb0405","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-020-3004-3","article-title":"Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline","volume":"589","author":"Guo","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130781_bb0410","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: its emergence, mechanism, and prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0415","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1128\/AAC.01418-13","article-title":"Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug","volume":"58","author":"McLeay","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130781_bb0420","first-page":"60","article-title":"B\u00e9daquiline\u00a0: De l'in Vitro Aux Essais Cliniques d'un Nouvel Antituberculeux","volume":"17","author":"Guglielmetti","year":"2015","journal-title":"J Antiinfect"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130781_bb0425","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2666-5247(23)00002-2","article-title":"Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis","volume":"4","author":"Sonnenkalb","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.bmcl.2026.130781_bb0430","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmcl.2026.130781_bb0435","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with non-tuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.bmcl.2026.130781_bb0440","doi-asserted-by":"crossref","first-page":"S1321","DOI":"10.1093\/clinids\/11.Supplement_5.S1321","article-title":"Use of quinolones in urinary tract infections and prostatitis","volume":"11","author":"Naber","year":"1989","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020371","article-title":"DNA gyrase as a target for quinolones","volume":"11","author":"Spencer","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bmcl.2026.130781_bb0450","doi-asserted-by":"crossref","DOI":"10.1007\/s00706-021-02806-7","article-title":"Fluoroquinolones: a review on anti-tubercular activity","author":"Joshi","year":"2021","journal-title":"Monatsh Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0455","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/bfgp\/elac029","article-title":"Targeting novel sites in DNA gyrase for development of anti-microbials","volume":"22","author":"Salman","year":"2023","journal-title":"Brief Funct Genomics"},{"key":"10.1016\/j.bmcl.2026.130781_bb0460","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/dkr566","article-title":"A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system","volume":"67","author":"Maruri","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0465","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","article-title":"Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes","volume":"50","author":"Aubry","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106385","article-title":"Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance","volume":"58","author":"Chaiyachat","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmcl.2026.130781_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001746","article-title":"Mycobacterium tuberculosis Ser\/Thr protein kinase B mediates an oxygen-dependent replication switch","volume":"12","author":"Ortega","year":"2014","journal-title":"PLoS Biol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0480","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12941-017-0234-9","article-title":"PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. tuberculosis","volume":"16","author":"Gupta","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.bmcl.2026.130781_bb0485","doi-asserted-by":"crossref","first-page":"32244","DOI":"10.1021\/acsomega.3c02563","article-title":"Overcoming Mycobacterium tuberculosis drug resistance: novel medications and repositioning strategies","volume":"8","author":"Sachan","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2026.130781_bb0490","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmcl.2026.130781_bb0495","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria","volume":"74","author":"Ruth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0500","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01798-16","article-title":"In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex","volume":"61","author":"Brown-Elliott","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0505","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17512433.2016.1200462","article-title":"Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis","volume":"9","author":"Nguyen","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0510","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.bmcl.2026.130781_bb0515","article-title":"Current advances in developing new antimicrobial agents against non-tuberculous Mycobacterium","volume":"14","author":"Cross","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.bmcl.2026.130781_bb0520","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00945-24","article-title":"TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus","volume":"68","author":"Fan","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130781_bb0525","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01412-21","article-title":"Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis","volume":"65","author":"Almeida","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0530","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02404-19","article-title":"TBAJ-876, a 3,5-dialkoxypyridine analogue of bedaquiline, is active against Mycobacterium abscessus","volume":"64","author":"Sarathy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25061423","article-title":"Synthetic studies to help elucidate the metabolism of the preclinical candidate TBAJ-876\u2014a less toxic and more potent analogue of bedaquiline","volume":"25","author":"Choi","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130781_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00401-9","article-title":"Phase 2 trial of a novel tuberculosis drug launched","volume":"5","author":"Holt","year":"2024","journal-title":"Lancet Microbe"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130781_bb0545","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00613-24","article-title":"Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects","volume":"68","author":"Lombardi","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0550","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S390187","article-title":"In vitro and intracellular antibacterial activity of sudapyridine (WX-081) against tuberculosis","volume":"16","author":"Xiao","year":"2023","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.bmcl.2026.130781_bb0555","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13718","article-title":"Safety, pharmacokinetics, and food effect of sudapyridine (WX-081), a novel anti-tuberculosis candidate in healthy Chinese subjects","volume":"17","author":"Yu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.bmcl.2026.130781_bb0560","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00518-23","article-title":"Sudapyridine (WX-081) antibacterial activity against Mycobacterium avium, Mycobacterium abscessus, and Mycobacterium chelonae in vitro and in vivo","volume":"9","author":"Zheng","year":"2024","journal-title":"mSphere"},{"key":"10.1016\/j.bmcl.2026.130781_bb0565","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s12890-025-04004-1","article-title":"Clinical efficacy of sitafloxacin-containing regimens for Mycobacterium avium complex pulmonary disease","volume":"25","author":"Urabe","year":"2025","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.bmcl.2026.130781_bb0570","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.779531","article-title":"Sitafloxacin expresses potent anti-Mycobacterium abscessus activity","volume":"12","author":"He","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21216","article-title":"Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China","volume":"9","author":"Kong","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bmcl.2026.130781_bb0580","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2169\/internalmedicine.6189-20","article-title":"Bursitis, bacteremia, and disseminated infection of Mycobacteroides (Mycobacterium) abscessus subsp. massiliense","volume":"60","author":"Oka","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.bmcl.2026.130781_bb0585","doi-asserted-by":"crossref","unstructured":"Takano, K.; Shimada, D.; Kashiwagura, S.; Kamioka, Y.; Hariu, M.; Watanabe, Y.; Seki, M. Severe pulmonary Mycobacterium abscessus cases due to co-infection with other microorganisms well treated by clarithromycin and sitafloxacin in Japan. IMCRJ 2021, Volume 14, 465\u2013470, doi:https:\/\/doi.org\/10.2147\/IMCRJ.S321969.","DOI":"10.2147\/IMCRJ.S321969"},{"key":"10.1016\/j.bmcl.2026.130781_bb0590","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/03007995.2021.1885362","article-title":"A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia","volume":"37","author":"Li","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bmcl.2026.130781_bb0595","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2026.130781_bb0600","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0605","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.47.5.1736-1738.2003","article-title":"In vitro activity of linezolid against slowly growing nontuberculous mycobacteria","volume":"47","author":"Brown-Elliott","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0610","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/AAC.45.3.764-767.2001","article-title":"Activities of linezolid against rapidly growing mycobacteria","volume":"45","author":"Wallace","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0615","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1016\/j.ejmech.2011.07.049","article-title":"Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties","volume":"46","author":"Thomas","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0620","doi-asserted-by":"crossref","DOI":"10.1038\/srep46696","article-title":"Functional, thermodynamics, structural and biological studies of in silico-identified inhibitors of Mycobacterium tuberculosis enoyl-ACP(CoA) reductase enzyme","volume":"7","author":"Martinelli","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2026.130781_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114908","article-title":"Novel 4-aminoquinolines: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase, antitubercular activity, SAR, and preclinical evaluation","volume":"245","author":"Paz","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0630","article-title":"Mefloquine and its enantiomers are active against Mycobacterium tuberculosis in vitro and in macrophages","volume":"2014","author":"Bermudez","year":"2014","journal-title":"Tuberc Res Treat"},{"key":"10.1016\/j.bmcl.2026.130781_bb0635","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00320-12","article-title":"Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice","volume":"56","author":"Bermudez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0640","article-title":"The antimalarial mefloquine shows activity against Mycobacterium abscessus, inhibiting mycolic acid metabolism","volume":"22","author":"Degiacomi","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.bmcl.2026.130781_bb0645","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/AAC.43.8.1870","article-title":"Mefloquine is active in vitro and in vivo against Mycobacterium avium complex","volume":"43","author":"Bermudez","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0650","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0311167","article-title":"Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection","volume":"19","author":"Froment","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2026.130781_bb0655","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.46.6.1680-1687.2002","article-title":"Mefloquine and new related compounds target the F0 complex of the F0F1 H+-ATPase of Streptococcus pneumoniae","volume":"46","author":"Mart\u00edn-Galiano","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104786","article-title":"Mefloquine synergism with anti-tuberculosis drugs and correlation to membrane effects: biologic, spectroscopic and molecular dynamics simulations studies","volume":"110","author":"Dos Santos","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0665","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1470891","article-title":"Progress in the study of mefloquine as an antibiotic adjuvant for combination bacterial inhibition treatment","volume":"14","author":"Liang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0670","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bmc.2011.11.006","article-title":"Mefloquine\u2013oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: in vitro activity including against the multidrug-resistant tuberculosis strain T113","volume":"20","author":"Gon\u00e7alves","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0675","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijantimicag.2016.04.029","article-title":"Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection","volume":"48","author":"Rodrigues-Junior","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmcl.2026.130781_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105596","article-title":"Antibacterial activity of new substituted 4-N-alkylated-2-trifluoromethyl-quinoline analogues against sensitive and resistant Mycobacterium tuberculosis strains","volume":"157","author":"Da Silva","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bmcl.2026.130781_bb0685","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bmcl.2009.12.045","article-title":"Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents","volume":"20","author":"Eswaran","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130781_bb0690","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1016\/j.bmc.2015.06.047","article-title":"Ring-substituted 8-hydroxyquinoline-2-carboxanilides as potential antimycobacterial agents","volume":"23","author":"Kos","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0695","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/molecules17010613","article-title":"Investigating the spectrum of biological activity of substituted quinoline-2-carboxamides and their isosteres","volume":"17","author":"Gonec","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130781_bb0700","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/acsmedchemlett.5b00324","article-title":"2-(Quinolin-4-yloxy)acetamides are active against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains","volume":"7","author":"Pissinate","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130781_bb0705","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ejmech.2016.11.048","article-title":"New insights into the SAR and drug combination synergy of 2-(Quinolin-4-Yloxy)Acetamides against Mycobacterium tuberculosis","volume":"126","author":"Giacobbo","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112179","article-title":"Design, synthesis, and evaluation of new 2-(Quinoline-4-Yloxy)Acetamide-based antituberculosis agents","volume":"192","author":"Borsoi","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0715","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijantimicag.2017.08.023","article-title":"Activity of 2-(Quinolin-4-Yloxy)Acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing","volume":"51","author":"Subtil","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmcl.2026.130781_bb0720","doi-asserted-by":"crossref","first-page":"21781","DOI":"10.1021\/acs.jmedchem.4c01302","article-title":"Unveiling the antimycobacterial potential of novel 4-alkoxyquinolines: insights into selectivity, mechanism of action, and in vivo exposure","volume":"67","author":"Da Silva","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0725","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/ml300362a","article-title":"Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives","volume":"4","author":"Tukulula","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130781_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050576","article-title":"New quinoline\u2013urea\u2013benzothiazole hybrids as promising antitubercular agents: synthesis, in vitro antitubercular activity, cytotoxicity studies, and in silico ADME profiling","volume":"15","author":"Moodley","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmcl.2026.130781_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106904","article-title":"Synthesis, characterization, in vitro antimycobacterial and cytotoxicity evaluation, DFT calculations, molecular docking and ADME studies of new isomeric benzimidazole-1,2,3-triazole-quinoline hybrid mixtures","volume":"141","author":"Nyoni","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0740","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/AAC.03913-14","article-title":"Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs","volume":"59","author":"Blanco","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0745","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.ejmech.2011.03.039","article-title":"New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents","volume":"46","author":"Thomas","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0750","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.bmc.2015.03.004","article-title":"Design and synthesis of novel quinoline\u2013aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors","volume":"23","author":"Medapi","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0755","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ejmech.2014.09.029","article-title":"Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety","volume":"86","author":"Liu","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0760","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejmech.2015.09.030","article-title":"Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety","volume":"104","author":"Zhang","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130781_bb0765","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1016\/j.ejmech.2009.04.041","article-title":"Synthesis and in vitro antibacterial activity of 7-(4-alkoxyimino-3-amino-3-methylpiperidin-1-yl)fluoroquinolone derivatives","volume":"44","author":"Chai","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0770","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jfluchem.2018.01.007","article-title":"Synthesis and antimycobacterial evaluation of new (2-oxo-2H-chromen-3-yl) substituted fluoroquinolones","volume":"208","author":"Charushin","year":"2018","journal-title":"J Fluorine Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102952","article-title":"Design, synthesis and molecular docking of new N-4-piperazinyl ciprofloxacin-triazole hybrids with potential antimicrobial activity","volume":"88","author":"Mohammed","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112821","article-title":"Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis","volume":"207","author":"Coulibaly","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0785","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1016\/j.bmc.2013.09.034","article-title":"Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids","volume":"21","author":"Rodrigues","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0790","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.3390\/molecules20058800","article-title":"Design, synthesis and antitubercular activity of certain nicotinic acid hydrazides","volume":"20","author":"Eldehna","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2026.130781_bb0795","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejmech.2017.07.004","article-title":"Design, synthesis and 2D QSAR study of novel pyridine and quinolone hydrazone derivatives as potential antimicrobial and antitubercular agents","volume":"138","author":"Abdelrahman","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112045","article-title":"Synthesis and antimycobacterial activity of thiazolidine-2,4-dione based derivatives with halogenbenzohydrazones and pyridinecarbohydrazones substituents","volume":"189","author":"Trotsko","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130781_bb0805","first-page":"496","article-title":"Synthesis of new thiazolidine-2,4-dione derivatives and their antimicrobial and antitubercular activity","volume":"1","author":"Shaikh","year":"2013","journal-title":"Indian J Res Pharm Biotechnol"},{"key":"10.1016\/j.bmcl.2026.130781_bb0810","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/cmdc.201402171","article-title":"Structure-guided design of thiazolidine derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors","volume":"9","author":"Devi","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0815","doi-asserted-by":"crossref","DOI":"10.1186\/s13065-018-0496-0","article-title":"Synthesis, SAR and in vitro therapeutic potentials of thiazolidine-2,4-diones","volume":"12","author":"Sucheta","year":"2018","journal-title":"Chem Cent J"},{"key":"10.1016\/j.bmcl.2026.130781_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.jics.2024.101346","article-title":"Design, synthesis and docking studies of new molecular hybrids bearing benzimidazole and thiazolidine-2,4-dione as potential antitubercular agents","volume":"101","author":"Raghu","year":"2024","journal-title":"J Indian Chem Soc"},{"key":"10.1016\/j.bmcl.2026.130781_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.110902","article-title":"Assessment of anti-hyperglycemic and anti-hyperlipidemic effects of thiazolidine-2,4-dione derivatives in HFD-STZ diabetic animal model","volume":"391","author":"Fettach","year":"2024","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.bmcl.2026.130781_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113668","article-title":"Design and synthesis of 2-(2-Isonicotinoylhydrazineylidene)Propanamides as InhA inhibitors with high antitubercular activity","volume":"223","author":"Pfl\u00e9gr","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0835","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121302","article-title":"Design and synthesis of highly active antimycobacterial mutual esters of 2-(2-Isonicotinoylhydrazineylidene)Propanoic acid","volume":"14","author":"Pfl\u00e9gr","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bmcl.2026.130781_bb0840","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01956-19","article-title":"Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis","volume":"64","author":"Walsh","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0845","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/jm9010719","article-title":"Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance","volume":"52","author":"De Carvalho","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0850","doi-asserted-by":"crossref","first-page":"18333","DOI":"10.1039\/D2RA02163C","article-title":"Pyridine appended 2-Hydrazinylthiazole derivatives: design, synthesis, in vitro and in silico antimycobacterial studies","volume":"12","author":"Matsa","year":"2022","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmcl.2026.130781_bb0855","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1086\/428839","article-title":"Nitazoxanide: a new thiazolide antiparasitic agent","volume":"40","author":"Fox","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115617","article-title":"Antimycobacterial pyridine carboxamides: from design to in vivo activity","volume":"258","author":"Nawrot","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0865","article-title":"Activity of pyrazinamide against Mycobacterium tuberculosis at neutral pH in PZA-S1 minimal medium","volume":"10","author":"Shi","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.bmcl.2026.130781_bb0870","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01465-21","article-title":"Decreased methylenetetrahydrofolate reductase activity leads to increased sensitivity to para-aminosalicylic acid in Mycobacterium tuberculosis","volume":"66","author":"Yu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0875","doi-asserted-by":"crossref","DOI":"10.2147\/DDDT.S566020","article-title":"Investigation of potent anti-Mycobacterium tuberculosis agents derived from pyridine derivatives targeting the enoyl acyl carrier protein reductase (InhA): design, synthesis, and computational analysis","volume":"20","author":"Sabt","year":"2026","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmcl.2026.130781_bb0880","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1039\/D5MD00997A","article-title":"Design, synthesis, and molecular modeling of novel thiazolopyridine-based inhibitors of enoyl acyl carrier protein reductase (InhA) as anti-Mycobacterium tuberculosis agents","volume":"17","author":"Sabt","year":"2026","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128604","article-title":"Design, synthesis and molecular docking studies of imidazole and benzimidazole linked ethionamide derivatives as inhibitors of InhA and antituberculosis agents","volume":"60","author":"Raghu","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130781_bb0890","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejmech.2015.10.008","article-title":"Structure activity relationships of 4-hydroxy-2-pyridones: a novel class of antituberculosis agents","volume":"106","author":"Ng","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130781_bb0895","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tube.2017.09.003","article-title":"Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA","volume":"107","author":"McNeil","year":"2017","journal-title":"Tuberculosis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0900","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01607-22","article-title":"In vitro and in vivo efficacy of NITD-916 against Mycobacterium fortuitum","volume":"67","author":"Roquet-Ban\u00e8res","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0905","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00249-25","article-title":"An Enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Mycobacterium abscessus activity","author":"Jia","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130781_bb0910","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1021\/acsinfecdis.2c00314","article-title":"Efficacy and mode of action of a direct inhibitor of Mycobacterium abscessus InhA","volume":"8","author":"Alcaraz","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130781_bb0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116806","article-title":"Design and synthesis of thieno[3, 2-b]pyridinone derivatives exhibiting potent activities against Mycobacterium tuberculosis in vivo by targeting Enoyl-ACP reductase","volume":"279","author":"Liang","year":"2024","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:35:29Z","timestamp":1792067729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26002489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":183,"alternative-id":["S0960894X26002489"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130781","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinolin(on)es and pyridin(on)es as promising scaffolds against mycobacterial infections","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130781"}}